Clinical trials: Amyloid-beta
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Dementia, Alzheimer Disease
Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid
The early detection of a preclinical AD or early stage of AD with amyloid imaging could improve the diagnosis and provide knowledge for better therapeutical approach by combining the best of imaging: structural MR sequences and…
- Trial name
- NCT02343757
- Testing
- PET/MRI
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University Hospitals Cleveland Medical Center
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease
A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.
To test that LY450139, a gamma-secretase inhibitor, will reduce the rate of newly synthesize Amyloid Beta by determining the amount of newly synthesized 13C6 leucine-labeled Amyloid Beta in lumbar cerebrospinal fluid from…
- Trial name
- NCT00765115
- Testing
- LY450139
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Using Hypnotherapy For Dementia & Alzheimer's
From the past research that has been done the investigators have learned that brain cells die \& leave a deposit in the brain known as beta-amyloid.
- Trial name
- NCT01435551
- Testing
- Hypnotherapy
- Sponsor
- Families To The Rescue
Dementia, Alzheimer's Disease
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
To Determine the the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology
- Trial name
- NCT01886820
- Testing
- [18F]NAV4694
- Where
- 15 sites in United States
- Volunteers
- 290 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer's Disease
Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease
The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed…
- Trial name
- NCT01189084
- Testing
- Observational
- Where
- 2 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- United Biomedical
Alzheimer Disease
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- AV94 (NCT00605059)
- Testing
- [123I]AV94
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Dementia
Triglyceride-rich Lipoprotein and Development of Dementia
Because of the rapid aging of the global population, dementia has become a serious problem, and Alzheimer's disease (AD) is the most common cause of dementia.
- Trial name
- NCT02814422
- Where
- Taiwan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain…
- Trial name
- MNI-558 (NCT01217021)
- Testing
- [18F] MNI-558
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Trial name
- NCT06439992
- Testing
- 18F-Fluselenamyl
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics
Introduction: Alzheimer's disease (AD) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (Abeta).
- Trial name
- AWAKE (NCT01194713)
- Testing
- Sleep deprivation
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University Medical Center Nijmegen
Alzheimer Disease
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
Purpose: The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography…
- Trial name
- AV151 (NCT00605046)
- Testing
- SPECT scan
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimers Disease
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects
The underlying goal of this study is to assess 123-I AV39 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00439010
- Testing
- [123I] AV 39
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Subarachnoid Hemorrhage, Terson Syndrome
The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage
Prospective clinical study to investigate the pathogenesis of Terson syndrome and the prognostic value of the CSF-biomarkers tau-protein and amyloid-β 40 and 42 in patients with aneurysmatic subarachnoid hemorrhage.
- Conditions
- Subarachnoid Hemorrhage, Terson Syndrome, CSF-proteines
- Trial name
- NCT02129010
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Holger Joswig
Alzheimer Disease
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00544453
- Testing
- [123I] MNI-308
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease, Alzheimer Dementia
Study to Evaluate Amyloid in Blood and Imaging Related to Dementia
The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease.
- Trial name
- SEABIRD (NCT03899844)
- Testing
- Blood collection, PiB PET/MRI, and cognitive testing
- Where
- United States
- Volunteers
- 1,122 people
- Sponsor
- Washington University School of Medicine
Disseminated Sclerosis
A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).
In multiple sclerosis (MS) sub cortical cognitive impairments are frequently reported. Nevertheless, cortical cognitive troubles, with hippocampic memory troubles have been described.
- Trial name
- BioCogS (NCT00978536)
- Testing
- Cognitive impairment of multiple sclerosis
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital